The Effects of ECMO on the Pharmacokinetics of Hydromorphone

Phase 2 Recruiting 26 enrolled Xiaobo Yang, MD

NaSequentialOpen-labelTreatment

Summary

The purpose of this study was to establish a population pharmacokinetic (PPK) model of hydromorphone in patients under ECMO, and to recommend a dosing regimen when the target effective concentration was reached.

Timeline

Start: 2022-01-01
Primary completion: 2024-09-01
Completion: 2024-09-01

Publications

Gao X, Yao L, Zeng F, Zhang H, Wu Y, Huang Y, Hong Z, Shu H, Zhang J, Yang X, Zou X, Shang Y. Population Pharmacokinetics of Intravenous Infusion of Hydromorphone in Critically Ill Patients Supported by Extracorporeal Membrane Oxygenation. Clin Transl Sci. 2026 Jul;19(7):e70666. doi: 10.1111/cts.70666.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Hydromorphone	Other / unclassified	0.03 mg/kg	Intravenous

Indications

No indication recorded.